Validity of all the instruments
measuring QoL was confirmed.
Study findings suggest that QUALIDEM is the preferred instrument to evaluate QoL of residents in SHA, especially due to the high acceptability. Further research is needed to develop and improve these existing measurements.”
“Study Design. Retrospective cross-sectional study.
Objective. To evaluate the degree of postoperative pain and patients’ satisfaction after lumbar fusion from a nationwide survey in Korea.
Summary of Background Data. There have been few studies that investigated the factors related to patients’ satisfaction after spinal fusion in lumbar degenerative disease (LDD).
Methods. This study included 629 patients who underwent spinal fusion for LDD at clinics of designated members of the Korean Society of Spine Surgery. This survey was done in 123 hospitals with 171 spine surgeons. Questionnaires for patients included severity of present back pain and radicular pain GSK1904529A cost ( visual analog scale score), Oswestry Disability
Index (ODI), and subjective outcomes. Questionnaire buy AZD7762 for surgeons included preoperative diagnosis, level of fusion, operative method, and presumed patient’s pain.
Results. The patients were 199 men and 430 women, with mean age of 62.3 years. The mean visual analog scale score of back pain and radicular pain was 5.0 +/- 2.6 and 4.4 +/- 3.0, respectively. The mean ODI was 44.3 +/- 19.4. ODI was significantly increased with older age, workers’ compensation, and increased fusion extent. Correlated factors of dissatisfaction Staurosporine manufacturer were severe back pain, higher ODI, multiple operation, and insufficient explanation about postoperative pain. There was a significant correlation between preoperative explanation about postoperative pain and degree of patient’s
pain.
Conclusion. Patients’ satisfaction was not as high as expected after fusion for LDD. Therefore, the decision for performing a lumbar fusion in those patients must be done more carefully, and it should be explained more precisely that chronic pain may persist after spinal surgery.”
“This 24-week, multicenter, open-label trial was designed to evaluate the dosing, effectiveness, and safety of topiramate monotherapy for epilepsy and to identify patient and clinical characteristics predictive of optimally effective stabilized monotherapy doses. Of 406 randomized patients, 244 comprised the evaluable-for-efficacy Population (>= 12 weeks of treatment and stabilized topiramate dose during final 28 days): 2 13 were on topiramate monotherapy at the end of the trial. The mean stabilized daily dose of topiramate over the last 28 days of treatment (primary endpoint) was significantly lower for patients reporting one to three seizures (low seizure frequency, n = 147) than for those reporting more than three seizures (high seizure frequency, it = 66) during a 3-month retrospective baseline period (191 mg vs 239 mg, P = 0.003).